Search Results - "Lypova, Nadiia"

Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq by Lanceta, Lilibeth, Lypova, Nadiia, O’Neill, Conor, Li, Xiaohong, Rouchka, Eric, Chesney, Jason, Imbert-Fernandez, Yoannis

“…Purpose The management of triple-negative breast cancer (TNBC) remains a significant clinical challenge due to the lack of effective targeted therapies…”
Get full text

PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs by Lypova, Nadiia, Dougherty, Susan M., Lanceta, Lilibeth, Chesney, Jason, Imbert-Fernandez, Yoannis

“…Tyrosine kinase inhibitors (TKIs) targeting the kinase domain of the epidermal growth factor receptor (EGFR), such as erlotinib, have dramatically improved…”
Get full text

Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy by Lypova, Nadiia, Lanceta, Lilibeth, Gibson, Alana, Vega, Stephanie, Garza-Morales, Rodolfo, McMasters, Kelly M, Chesney, Jason, Gomez-Gutierrez, Jorge G, Imbert-Fernandez, Yoannis

“…While clinical responses to palbociclib have been promising, metastatic breast cancer remains incurable due to the development of resistance. We generated…”
Get full text

Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non–small cell lung cancer cell survival by Lypova, Nadiia, Telang, Sucheta, Chesney, Jason, Imbert-Fernandez, Yoannis

“…Constitutive activation of the epidermal growth factor receptor (EGFR) because of somatic mutations of the EGFR gene is commonly observed in tumors of…”
Get full text

Abstract 1052: 6-phosphofructo-2-kinase enhances cytotoxicity of the EGFR inhibitor erlotinib via regulation of cell cycle in non-small lung cancer cell lines by Lypova, Nadiia, Lanceta, Lilibeth, Chesney, Jason, Imbert-Fernandez, Yoannis

“…Lung tumor development and aggressiveness is largely driven by a multitude of oncogenes including the epidermal growth factor receptor (EGFR). Targeted EGFR…”
Get full text

Abstract 6001: 6-Phosphofructo-2-kinase inhibition to increase the efficacy of ER and CDK4/6 inhibitors against ER+ breast cancer by Lanceta, Lilibeth, Lypova, Nadiia, Chesney, Jasson, Imbert-Fernandez, Yoannis

“…Deregulation of the estrogen receptor (ER)-cyclin D1-CDK4/6 pathway is a hallmark of ER+ breast cancer that has prompted the development of CDK4/6 inhibitors…”
Get full text

Abstract 6202: 6-Phosphofructo-2-kinase in regulating DNA damage and repair in EGFR-driven lung cancer by Lypova, Nadiia, Lanceta, Lilibeth, Dougherty, Susan, Chesney, Jason, Imbert-Fernandez, Yoannis

“…Activating mutations of epidermal growth factor receptor (mutEGFR) are established drivers of lung tumor development, aggressiveness, and resistance to…”
Get full text

Abstract P1-13-18: EGFR signaling contributes to acquired resistance to CDK4/6 inhibitors in ER+ breast cancer cells in vitro and in vivo by Lypova, Nadiia, Lanceta, Lilibeth, Daugherty, Susan, Chesney, Jason, Imbert-Fernandez, Yoannis

“…Breast cancer driven by different hormone receptors, including estrogen receptor (ER+), is responsible for approximately 70-80% of cases among women. While…”
Get full text

Abstract 1772: EGFR signaling as a mechanism of resistance to CDK4/6 inhibitors in Palbociclib-resistant ER+ breast cancer cells by Lypova, Nadiia, Lanceta, Lilibeth, Dougherty, Susan M., Chesney, Jason A., Imbert-Fernandez, Yoannis

“…Breast cancer driven by estrogen receptor (ER) is responsible for approximately 60-70% of cases among women. Selective inhibition of cyclin-dependent kinases 4…”
Get full text

Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer Cells by Lanceta, Lilibeth, O'Neill, Conor, Lypova, Nadiia, Li, Xiahong, Rouchka, Eric, Waigel, Sabine, Gomez-Gutierrez, Jorge G, Chesney, Jason, Imbert-Fernandez, Yoannis

“…Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) inhibition in estrogen receptor-positive (ER+) breast cancer remains a significant clinical…”
Get full text

Abstract 4478: 6-Phosphofructo-2-Kinase (PFKFB3): At the crossroads of resistance to targeted cancer therapies by Telang, Sucheta, O'Neal, Julie, Imbert-Fernandez, Yoannis, Clem, Brian, Lypova, Nadiia, Tapolsky, Gilles H., Trent, John, Chesney, Jason

“…Targeted cancer therapies that block the growth and spread of cancer by interfering with specific onco-proteins are limited by signaling mechanisms that drive…”
Get full text